KromaTiD, Inc.

Fort Collins, CO · Founded 2022 · Biotech · Private

K-Band dGH, an in-situ hybridization method using high-density chromatid paints to detect and characterize structural variants in chromosomes

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026 · kromatid.com

Sector: Biotech
Headquarters: Fort Collins, CO
Founded: 2022
Latest Form D: $3.5M, Jul 2025
Total capital: $20.5M

Federal grants: $4.8M; 6 awards · 2018–2021; Rank in peer group#15 of 42
Private capital raised: $15M; 6 Form D · last Jul 2025; 16 months since last filing
Federal contracts: $726K; 3 awards · NASA, Health and Human S; Rank in Biotech#211 of 4373
Granted patents: 0; 16 pending

Capital timeline

Latest events

Jul 2025Private capital raisedForm D · SEC · 6th filing$3.5M
Jan 2024Private capital raisedForm D · SEC · 5th filing$2.1M
Dec 2021Federal grantHealth and Human S · Phase II · A comprehensive quality control testing strategy for engineered cells$350K
Oct 2021Private capital raisedForm D · SEC · 4th filing$7.9M
Jul 2021Federal grantHealth and Human S · Phase II · Automated, high-throughput identification of genetic structural variants for gene editing and undiagnosed genetic diseases screening$584K
Jan 2021Federal grantHealth and Human S · Phase II · A comprehensive quality control testing strategy for engineered cells$1.3M
Aug 2020Federal grantHealth and Human S · Phase II · Automated, high-throughput identification of genetic structural variants for gene editing and undiagnosed genetic diseases screening$1.7M
Feb 2019Private capital raisedForm D · SEC · 3rd filing$850K
Jan 2017Private capital raisedForm D · SEC · 2nd filing$623K
Sep 2013Private capital raisedForm D · SEC · 1st filing$50K

Show 5 earlier federal awards

Sep 2019Federal contractHealth and Human S · Assay Development Karyotyping Services$26K
May 2019Federal grantHealth and Human S · Phase II · Rapid, cost-effective whole genome screening tools for cryptic inversions and translocations$701K
Jul 2018Federal grantHealth and Human S · Phase II · Rapid, cost-effective whole genome screening tools for cryptic inversions and translocations$207K
Jan 2010Federal contractNASA · We Propose The Continued Development Of A Novel Approach To The Detection Of Chromosomal Inversions. Transmissible Chromosome Aberrations (translocations And Inversions) Have Profound Genetic Effects, Such As Disrupting Regulatory Sequences That Control Gene Expression, Or Creating Genetic Chimeras. These Chromosome Aberrations Play A Causative Role In Cancer, And Ionizing Radiation Is One Of The Most Efficient Agents Known To Induce Them. As Such, Chromosome Aberrations Are Relevant To Three Na$600K
Jan 2009Federal contractNASA · We Propose A Novel Approach To The Detection Of Chromosomal Inversions. Transmissible Chromosome Aberrations (translocations And Inversions) Have Profound Genetic Effects, Such As Disrupting Regulatory Sequences That Control Gene Expression, Or Creating Genetic Chimeras. These Chromosome Aberrations Play A Causative Role In Cancer, And They Are Induced By Radiation. As Such, Chromosome Aberrations Are Relevant To Three NASA Needs, Biodosimetry, Analysis Of Astronaut Lymphocytes For Cumulative Ra$100K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Federal first

55months

from KromaTiD, Inc.’s first federal award to its first private round.

First federal award · Jan 2009: NASA · $100K
First Form D · Sep 2013: $50K · 1st Form D
Awards before first raise: 2 awards

An association in public records, not a cause or a prediction.

Standing among 42 peers

Line = median

Biotech · Instrument

Federal grants#15 · top 36%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants

Christopher TompkinsResearcherExecutive Officer, DirectorLinked by $2.4M in grants as PI
Andrew JostExecutive OfficerNamed in SEC Form D filings
DAVID BRUNELDirectorNamed in SEC Form D filings
Gary J GrahamExecutive OfficerNamed in SEC Form D filings
Ginny OrndorfDirectorNamed in SEC Form D filings
Gordon LinkExecutive OfficerNamed in SEC Form D filings

Show all 17 people

Jack BallDirectorNamed in SEC Form D filings
James ChomasDirectorNamed in SEC Form D filings
Joel J BedfordDirectorNamed in SEC Form D filings
Lauren J CostantiniDirectorNamed in SEC Form D filings
NATHAN WOODExecutive Officer, DirectorNamed in SEC Form D filings
Nick SaccomanoDirectorNamed in SEC Form D filings
Priyadarshini GogoiDirectorNamed in SEC Form D filings
Susan BaileyExecutive OfficerNamed in SEC Form D filings
Terry OpgenorthDirectorNamed in SEC Form D filings
Vic MyerDirectorNamed in SEC Form D filings
WALTER YOUNGDirectorNamed in SEC Form D filings

What it has protected

USPTO · 0 granted of 16

May 14, 2026PendingMethods, Compositions, And Kits For Determining Chromosome Stability, Genotoxicity, And Insert NumberUSPTOApplication 18920537
Jan 30, 2025PendingMETHODS FOR ANALYZING CHROMOSOMES AND CHROMOSOMAL ABNORMALITIES USING dGH WITH FLUORESCENCE SORTING AND/OR ARRAYSUSPTOApplication 18714564
Oct 6, 2022PendingMethods For High Resolution Spectral Chromosome Banding To Detect Chromosomal AbnormalitiesUSPTOApplication 17806246

Show all 16 patent records

Methods, Compositions, And Kits For Determining Chromosome Stability, Genotoxicity, And Insert NumberMay 14, 2026 · Application 18920537Pending
METHODS FOR ANALYZING CHROMOSOMES AND CHROMOSOMAL ABNORMALITIES USING dGH WITH FLUORESCENCE SORTING AND/OR ARRAYSJan 30, 2025 · Application 18714564Pending
Methods For High Resolution Spectral Chromosome Banding To Detect Chromosomal AbnormalitiesOct 6, 2022 · Application 17806246Pending
High-throughput Methods For Detecting Chromosomal AbnormalitiesApplication 63366601Pending
High-throughput Methods For Detecting Chromosomal AbnormalitiesApplication 63366142Pending
Methods And Compositions For Determining And Ranking The Potential Instability, Oncogenicity, Genotoxicity And Relative Risks For Cellular Gene Therapies And Any Population Of CellsApplication 63366141Pending
Methods And Compositions For Determining And Ranking The Potential Instability, Oncogenicity, Genotoxicity And Relative Risks For Cellular Gene Therapies And Any Population Of CellsApplication 63363476Pending
High-throughput, High-resolution Methods For Detecting Chromosomal AbnormalitiesApplication 63264764Pending
Methods For High Resolution Spectral Chromosome Banding To Detect Chromosomal AbnormalitiesApplication PCTUS2020063786Pending
Methods for High Resolution Spectral Chromosome Banding to Detect Chromosomal AbnormalitiesApplication 62945850Pending
High Resolution Detection Of Chromosomal Abnormalities Using Non-repetitive Nucleic Acid ProbesApplication PCTUS2013049369Pending
Detection Of Chromosomal Abnormalities Using Non-repetitive Nucleic Acid ProbesApplication 61827133Pending
Detection Of Chromosomal Abnormalities Using Non-repetitive Nucleic Acid ProbesApplication 61784889Pending
Detection Of Chromosomal Abnormalities Using Non-repetitive Nucleic Acid ProbesApplication 61702516Pending
Methods, Compositions, And Kits For Determining Chromosome Stability, Genotoxicity, And Insert NumberApplication PCTUS2023066097Pending
Methods For Analyzing Chromosomes And Chromosomal Abnormalities Using Dgh With Fluorescence Sorting And/or ArraysApplication PCTUS2022080780Pending

RenBio, Inc.Similar federal contract value in Biotech · $749K in contracts
GEN1E LIFESCIENCES INC.Similar federal contract value in Biotech · $749K in contracts
GALEN BIOTECHNOLOGIES, LLCSimilar federal contract value in Biotech · $727K in contracts
APHIOS CORPORATIONSimilar federal contract value in Biotech · $723K in contracts
PREDICTIVE BIOLOGYSimilar federal contract value in Biotech · $654K in contracts
Perfinity Biosciences, Inc.Similar federal contract value in Biotech · $649K in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.